In this study, we hypothesized that the novel HDAC8 inhibitors, SPA3052 and SPA3074, might be possible therapeutics for IBD and evaluated their efficacy and underlying mechanisms of action using a DSS-induced colitis murine model. Here, HDAC8 is linked to inflammatory bowel disease.